Compare ORMP & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | ADAG |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | ORMP | ADAG |
|---|---|---|
| Price | $2.88 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 226.0K | 79.5K |
| Earning Date | 11-13-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | $2.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $1.30 |
| 52 Week High | $3.20 | $3.16 |
| Indicator | ORMP | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 48.90 |
| Support Level | $2.66 | $1.61 |
| Resistance Level | $3.19 | $1.92 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 46.30 | 51.06 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.